Sitagliptin/Metformin Sandoz 50/850 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/850 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptin/metformin sandoz 50/850 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/850 mg film coated tablet blister pack

sandoz pty ltd - metformin hydrochloride, quantity: 850 mg; sitagliptin hydrochloride monohydrate, quantity: 56.69 mg (equivalent: sitagliptin, qty mg) - tablet, film coated - excipient ingredients: hypromellose; sodium lauryl sulfate; croscarmellose sodium; povidone; sodium stearylfumarate; hyprolose; titanium dioxide; iron oxide red; triethyl citrate; purified talc; microcrystalline cellulose; iron oxide yellow - sitagliptin/metformin sandoz is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

Sitagliptin/Metformin Sandoz 50/1000 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/1000 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptin/metformin sandoz 50/1000 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/1000 mg film coated tablet blister pack

sandoz pty ltd - metformin hydrochloride, quantity: 1000 mg; sitagliptin hydrochloride monohydrate, quantity: 56.69 mg (equivalent: sitagliptin, qty mg) - tablet, film coated - excipient ingredients: iron oxide yellow; titanium dioxide; hyprolose; povidone; iron oxide red; sodium lauryl sulfate; triethyl citrate; purified talc; microcrystalline cellulose; sodium stearylfumarate; hypromellose; croscarmellose sodium - sitagliptin/metformin sandoz is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

Sitagliptin/Metformin Sandoz 50/500 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/500 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptin/metformin sandoz 50/500 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/500 mg film coated tablet blister pack

sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.69 mg (equivalent: sitagliptin, qty 50 mg); metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; triethyl citrate; hyprolose; povidone; hypromellose; purified talc; titanium dioxide; microcrystalline cellulose; sodium lauryl sulfate; sodium stearylfumarate; iron oxide red - sitagliptin/metformin sandoz is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

MSD-ERTUGLIFLOZIN-METFORMIN 7.5/500 ertugliflozin/metformin hydrochloride 7.5 mg/500 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-metformin 7.5/500 ertugliflozin/metformin hydrochloride 7.5 mg/500 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 500 mg; ertugliflozin pyroglutamic acid, quantity: 9.713 mg (equivalent: ertugliflozin, qty 7.5 mg) - tablet, film coated - excipient ingredients: crospovidone; sodium lauryl sulfate; microcrystalline cellulose; carnauba wax; povidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

MSD-ERTUGLIFLOZIN-METFORMIN 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-metformin 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 500 mg; ertugliflozin pyroglutamic acid, quantity: 3.238 mg (equivalent: ertugliflozin, qty 2.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; carnauba wax; povidone; sodium lauryl sulfate; magnesium stearate; crospovidone; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

MSD-ERTUGLIFLOZIN-METFORMIN 7.5/1000 ertugliflozin/metformin hydrochloride 7.5 mg/1000 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-metformin 7.5/1000 ertugliflozin/metformin hydrochloride 7.5 mg/1000 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 1000 mg; ertugliflozin pyroglutamic acid, quantity: 9.713 mg (equivalent: ertugliflozin, qty 7.5 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; povidone; magnesium stearate; crospovidone; carnauba wax; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

MSD-ERTUGLIFLOZIN-METFORMIN 2.5/1000 ertugliflozin/metformin hydrochloride 2.5 mg/1000 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-metformin 2.5/1000 ertugliflozin/metformin hydrochloride 2.5 mg/1000 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 1000 mg; ertugliflozin pyroglutamic acid, quantity: 3.238 mg (equivalent: ertugliflozin, qty 2.5 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; crospovidone; magnesium stearate; povidone; carnauba wax; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

SEGLUROMET- ertugliflozin and metformin hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

segluromet- ertugliflozin and metformin hydrochloride tablet, film coated

merck sharp & dohme llc - ertugliflozin pidolate (unii: mlu731k321) (ertugliflozin - unii:6c282481ip), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - ertugliflozin 2.5 mg - segluromet® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see warnings and precautions (5.2)]. - hypersensitivity to ertugliflozin, metformin, or any excipient in segluromet, reactions such as angioedema or anaphylaxis have occurred [see adverse reactions (6.2)]. - patients with severe renal impairment (egfr less than 30 ml/min/1.73 m2 ), end stage-renal disease (esrd), or on dialysis [see use in specific populations (8.6)] . - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. risk summary based on animal data showing adverse renal effects, from ertugliflozin, segluromet is not recommended during the second and third trimesters of pregnancy. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage r

SEGLUROMET 7.5/500 ertugliflozin/metformin hydrochloride 7.5mg/500mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

segluromet 7.5/500 ertugliflozin/metformin hydrochloride 7.5mg/500mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 500 mg; ertugliflozin pyroglutamic acid, quantity: 9.713 mg (equivalent: ertugliflozin, qty 7.5 mg) - tablet, film coated - excipient ingredients: crospovidone; carnauba wax; sodium lauryl sulfate; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; iron oxide red - segluromet (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

SEGLUROMET 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

segluromet 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 500 mg; ertugliflozin pyroglutamic acid, quantity: 3.238 mg (equivalent: ertugliflozin, qty 2.5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; carnauba wax; povidone; microcrystalline cellulose; sodium lauryl sulfate; titanium dioxide; hypromellose; hyprolose; iron oxide red - segluromet (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]